These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 9086151

  • 21. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
    Nindl I, Rindfleisch K, Lotz B, Schneider A, Dürst M.
    Int J Cancer; 1999 Jul 19; 82(2):203-7. PubMed ID: 10389753
    [Abstract] [Full Text] [Related]

  • 22. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK, Liu SJ, Cheung JL, Cheung TH, Yeo W, Chong P, Man S.
    J Med Virol; 2011 Jun 19; 83(6):1023-30. PubMed ID: 21503915
    [Abstract] [Full Text] [Related]

  • 23. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
    Luxton JC, Rowe AJ, Cridland JC, Coletart T, Wilson P, Shepherd PS.
    J Gen Virol; 1996 Jul 19; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
    [Abstract] [Full Text] [Related]

  • 24. Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.
    Sasagawa T, Inoue M, Tanizawa O, Yutsudo M, Hakura A.
    Jpn J Cancer Res; 1992 Jul 19; 83(7):705-13. PubMed ID: 1325428
    [Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.
    Clin Cancer Res; 2002 Dec 19; 8(12):3676-85. PubMed ID: 12473576
    [Abstract] [Full Text] [Related]

  • 26. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
    Jiang B, Xue M.
    Genet Mol Res; 2015 Sep 08; 14(3):10473-81. PubMed ID: 26400278
    [Abstract] [Full Text] [Related]

  • 27. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.
    Clin Cancer Res; 2004 May 01; 10(9):2954-61. PubMed ID: 15131030
    [Abstract] [Full Text] [Related]

  • 28. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A, Koskimaa HM, Welters MJ, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.
    J Transl Med; 2015 May 20; 13():163. PubMed ID: 25990808
    [Abstract] [Full Text] [Related]

  • 29. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ.
    J Gen Virol; 1996 Sep 20; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [Abstract] [Full Text] [Related]

  • 30. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
    Thornburg C, Boczkowski D, Gilboa E, Nair SK.
    J Immunother; 2000 Sep 20; 23(4):412-8. PubMed ID: 10916750
    [Abstract] [Full Text] [Related]

  • 31. Brief report: antibody response to E6, E7, and L1 proteins of human papillomavirus 16 in an Italian population.
    Di Lonardo A, Campo MS, Venuti A, Marcante ML.
    J Med Virol; 1994 Aug 20; 43(4):357-61. PubMed ID: 7964645
    [Abstract] [Full Text] [Related]

  • 32. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)].
    Sotlar K, Diemer D, Stubner A, Menton S, Menton M, Dietz K, Wallwiener D, Bültmann B.
    Verh Dtsch Ges Pathol; 2005 Aug 20; 89():195-200. PubMed ID: 18035691
    [Abstract] [Full Text] [Related]

  • 33. Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins.
    Chee YH, Namkoong SE, Kim DH, Kim SJ, Park JS.
    Gynecol Oncol; 1995 May 20; 57(2):226-31. PubMed ID: 7729739
    [Abstract] [Full Text] [Related]

  • 34. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Judd A, Moscicki AB, Canchola AJ, Hilton JF, Palefsky JM.
    Clin Diagn Lab Immunol; 1996 Mar 20; 3(2):205-10. PubMed ID: 8991637
    [Abstract] [Full Text] [Related]

  • 35. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
    Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S.
    Oncol Rep; 2012 Jul 20; 28(1):346-52. PubMed ID: 22484610
    [Abstract] [Full Text] [Related]

  • 36. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
    Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M.
    Cancer Immunol Immunother; 2012 Jan 20; 61(1):63-70. PubMed ID: 21842207
    [Abstract] [Full Text] [Related]

  • 37. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, Nakanishi T, Ito Y, Tsujimura K, Iwata K, Ito K, Kodera Y, Morishima Y, Kuzushima K, Takahashi T.
    Int J Cancer; 2007 Feb 01; 120(3):594-604. PubMed ID: 17096336
    [Abstract] [Full Text] [Related]

  • 38. Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer.
    Ghosh AK, Smith NK, Stacey SN, Glew SS, Connor ME, Arrand JR, Stern PL.
    Int J Cancer; 1993 Feb 20; 53(4):591-6. PubMed ID: 8382193
    [Abstract] [Full Text] [Related]

  • 39. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
    Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, Daemen T, van der Zee A.
    Int J Cancer; 2006 May 15; 118(10):2529-37. PubMed ID: 16353143
    [Abstract] [Full Text] [Related]

  • 40. Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women.
    Zhao J, Zhu J, Guo J, Zhu T, Zhong J, Liu M, Ruan Y, Liao S, Li F.
    J Med Virol; 2020 Mar 15; 92(3):372-381. PubMed ID: 31670402
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.